GlassScriptPhysician profile
Natasha Lewis
NPI 1639503550
$4,786.52
in general payments reported to CMS, 2019-2025
30 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $584 · 2022: $1,157 · 2023: $788 · 2024: $1,231 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,031 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,031.21 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $593.58 | 2021-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $545.11 | 2021-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $494.76 | 2021-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $431.00 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $261.27 | 2022-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $223.61 | 2021-2025 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $218.56 | 2021-2025 | Acthar, Terlivaz |
| Genzyme Corporation | $208.96 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $204.81 | 2023-2025 | |
| Vifor Pharma, INC. | $198.41 | 2021-2025 | Veltassa, Korsuva |
| Akebia Therapeutics INC | $191.80 | 2021-2025 | Auryxia, Vafseo |
| Lilly USA, LLC | $158.03 | 2023-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $121.39 | 2021-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $109.96 | 2022-2025 | Ultomiris |
| Medtronic, INC. | $104.23 | 2021-2023 | Ellipsys Vascular Access System |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $93.03 | 2022-2024 | Aranesp, Parsabiv, Krystexxa |
| Nxstage Medical, INC. | $92.43 | 2024-2025 | Nxstage System One |
| Horizon Therapeutics Plc | $86.35 | 2023 | Krystexxa |
| Daiichi Sankyo INC. | $79.93 | 2021-2022 | |
| Travere Therapeutics, INC. | $73.42 | 2022-2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $67.80 | 2022-2025 | Jynarque |
| Ani Pharmaceuticals, INC. | $49.03 | 2022-2024 | Purified Cortrophin Gel |
| Scpharmaceuticals INC. | $35.03 | 2024-2025 | |
| Ardelyx, INC. | $32.86 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.43 | 2024 | Jardiance |
| Pharmacosmos Therapeutics INC. | $20.90 | 2021 | |
| Novo Nordisk INC | $19.34 | 2025 | Ozempic, Rybelsus |
| Chiesi USA, INC. | $17.91 | 2025 | Elfabrio |
| Ultragenyx Pharmaceutical INC. | $16.40 | 2022 | |
| Cormedix INC. | $15.18 | 2024 | Defencath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natasha Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.